News >

Split-Dose Gemcitabine and Cisplatin Shows Good Responses in Neoadjuvant MIBC

Ariela Katz
Published: Thursday, Jun 22, 2017

Michael Williams, MD

Michael Williams, MD

Study results presented at the 2017 American Urological Association Annual Meeting demonstrated that split-doses of gemcitabine and cisplatin as neoadjuvant chemotherapy for treating muscle-invasive bladder cancer (MIBC) has a good pathologic response with a high safety profile.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x